Resistance mechanism for ibrutinib in marginal zone lymphoma
| Autor: | Arwa Shana'ah, Beth A. Christian, Jennifer A. Woyach, Kami J. Maddocks, Dan Jones, Narendranath Epperla, Sabarish Ayyappan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology medicine.medical_specialty Chronic lymphocytic leukemia Phases of clinical research chemistry.chemical_compound Piperidines Refractory Bone Marrow immune system diseases hemic and lymphatic diseases Internal medicine Agammaglobulinaemia Tyrosine Kinase Humans Medicine Protein Kinase Inhibitors Aged business.industry Adenine Waldenstrom macroglobulinemia Lymphoma B-Cell Marginal Zone Hematology medicine.disease Stimulus Report Lymphoma Pyrimidines chemistry Drug Resistance Neoplasm Ibrutinib Pyrazoles Mantle cell lymphoma Marginal zone B-cell lymphoma business |
| Zdroj: | Blood Advances. 3:500-502 |
| ISSN: | 2473-9537 2473-9529 |
| DOI: | 10.1182/bloodadvances.2018029058 |
| Popis: | Ibrutinib is approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who are progressing on at least 1 previous anti-CD20–based therapy. This approval was based on the results of a multicenter phase 2 study of ibrutinib in relapsed/refractory MZL (n = 60) that showed an overall response rate of 48% and a median progression-free survival of 14.2 months.1 Although mechanisms of acquired resistance to ibrutinib have been described in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and diffuse large B-cell lymphoma (DLBCL),2-6 none have been reported for MZL. Because more patients with relapsed/refractory MZL are receiving treatment with ibrutinib, it is important to explore the possible mechanisms of ibrutinib resistance and understand the outcomes for patients who progress on ibrutinib. Here, we present a case of acquired ibrutinib resistance in a patient with relapsed/refractory MZL who was treated with ibrutinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|